H-1-NMR STUDIES OF HUMAN URINE - URINARY ELIMINATION OF THE ANTICANCER DRUG CARBOPLATIN

Samples of urine from a patient obtained before and after treatment with 300 mg of the anticancer drug [Pt(II)(NH3)2(CBDCA)] (carboplatin, "Paraplatin", where CBCDA is 1,1-dicarboxycyclobutane) have been analysed using 500 MHz 1D and 2D H-1 NMR spectroscopy. Peaks for the intact drug and the free ligand CBDCA have been assigned and are present in a mol ratio of ca. 5:1. Only about one half of the total Pt in the sample was present as intact drug. Relative to creatinine and citrate, the excretion of hippurate increased by a factor of ca. 4 after drug treatment. This work suggests that NMR spectroscopy can play a valuable role in studies of carboplatin metabolism.